Search Orphan Drug Designations and Approvals
-
| Generic Name: | A ligand binding moiety to MDM2, a chemical linker, and a ligand binding moiety to an E3 ligase that leads to MDM2 degradation. |
|---|---|
| Date Designated: | 06/21/2023 |
| Orphan Designation: | Treatment of acute myeloid leukemia |
| Orphan Designation Status: | Designated |
| FDA Orphan Approval Status: | Not FDA Approved for Orphan Indication |
| Sponsor: |
Kymera Therapeutics 500 North Beacon St. Watertown, Massachusetts 02472 United States The sponsor address listed is the last reported by the sponsor to OOPD. |
*Data for the Date Designation Withdrawn or Revoked field are shown for designations withdrawn or revoked after 08/12/2013.
-







